GlassScriptPhysician profile
Adam Rafi
NPI 1356640825
$11,120.07
in general payments reported to CMS, 2019-2025
31 companies · $2,040 in 2025
The $2,040 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $501 · 2021: $1,704 · 2022: $3,260 · 2023: $1,219 · 2024: $1,937 · 2025: $2,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,333 · Travel and Lodging: $1,863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,332.65 |
| Travel and Lodging | $1,863.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,376.20 | 2022-2025 | Versacross Access Solution, Watchman Access System |
| Abbott Laboratories | $1,566.53 | 2020-2025 | Jot Dx, Diamondback Peripheral, Jeti |
| Janssen Pharmaceuticals, INC | $1,278.00 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,070.03 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $777.85 | 2019-2025 | Lifevest |
| Amgen INC. | $422.99 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $418.52 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $400.79 | 2019-2025 | Camzyos, Eliquis |
| Preventric Diagnostics, INC. | $384.19 | 2021 | |
| Pfizer INC. | $362.43 | 2019-2025 | |
| Medtronic, INC. | $271.16 | 2021-2025 | Corevalve Evolut R |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.75 | 2020-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $207.26 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Astrazeneca Pharmaceuticals LP | $189.72 | 2019-2024 | Farxiga, Brilinta |
| Shockwave Medical, INC | $174.34 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $168.39 | 2020-2024 | |
| Amarin Pharma, INC. | $156.75 | 2021 | |
| Medtronic Vascular, INC. | $143.69 | 2019-2020 | |
| Biotronik INC. | $137.06 | 2021-2024 | Orsiro Mission |
| Philips North America LLC | $131.76 | 2019 | |
| Recor Medical INC | $44.24 | 2024 | Paradise Renal Denervation System |
| Scpharmaceuticals INC. | $31.75 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $24.31 | 2023 | Evkeeza |
| Inari Medical, INC. | $23.48 | 2021 | |
| Heron Therapeutics, INC. | $19.64 | 2023 | Zynrelef |
| Novo Nordisk INC | $17.17 | 2025 | Wegovy |
| Azurity Pharmaceuticals, INC. | $16.53 | 2023 | Edarbi |
| Amryt Pharma Holdings LTD | $15.85 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.17 | 2021 | |
| Alnylam Pharmaceuticals INC. | $13.88 | 2022 | |
| Esperion Therapeutics, INC. | $12.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Rafi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.